Evidence map›Paper›PMID 32518881›Full record

ArticleKidney international reports2020

Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical)

Prince Singh, Fouad T Chebib, Andrea G Cogal, Dimitar K Gavrilov, Peter C Harris, John C Lieske

Open access · goldAbstract readCase Reports
In one paragraph

Article in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Hyperoxaluria: Diagnosis and Treatment.The Urologic clinics of North America · 2025
    Review
  3. Review
  4. Diagnosis and management of primary hyperoxalurias: best practices.Pediatric nephrology (Berlin, Germany) · 2024
    Review
  5. Infant primary hyperoxaluria type 1Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Observational
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Prince SinghDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Fouad T ChebibDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Andrea G CogalDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Dimitar K GavrilovDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
John C LieskeDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
Facilitating personalized medicine of monogenic stone patients by genetic characterizationR21TR003174 · NCATS · MAYO CLINIC ROCHESTER · PI HARRIS, PETER C., LIESKE, JOHN C · 2020 to 2021
$437k
NCATS NIH HHS R21 TR003174NIDDK NIH HHS U54 DK083908
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32518881
PMCPMC7270974
OpenAlexW3017030183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.